Skip to main content
SpringerLink
Log in

Quand faire de la chimiothérapie néoadjuvante? Ľutilisation de la chimiothérapie néoadjuvante chez des patientes atteintes de cancer du sein opérable (stades II et III)

  • Chapter
Le cancer du sein

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 534 Accesses

Abstrait

Le cancer du sein représente un problème majeur de santé publique. Depuis 1960, il constitue la première cause de décès par cancer chez la femme et son incidence ne cesse ďaugmenter. Actuellement, ce cancer touche une femme sur 10 et une femme sur 25 en meurt. En 2003, aux États-Unis, environ 211000 nouveaux cas et 40000 décès ont été déclarés. En France, ľétude de Hill et Doyon (3) rapporte 42000 nouveaux cas et 11000 décès pour ľannée 2000.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. S, Bougnoux P, Penault-Llorca F, et al. (2003) Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. British Journal of Cancer 88: 1339–45

    Article  PubMed  Google Scholar 

  2. Barni S, Visini M, Piazza E et al. (2002) Cisplatin-Epirubicin-Vinorelbine (PEV): a new neoadjuvant chemotherapy for stage T2-3/N0-2 breast cancer patients pts). Proc Annu Meet Am Soc Clin Oncol, 21: abstract 1961, p 37b

    Google Scholar 

  3. Bear HD, Anderson S, Brown A et al. (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast an Bowel Project Protocol B-27. J Clin Oncol, 21: 4165–74

    Article  PubMed  CAS  Google Scholar 

  4. Belembaogo E, Feillel V, Chollet P et al. (1992) Neoadjuvant chemotherapy in 126 operable breast cancers. European Journal of Cancer 28: 896–900

    Article  Google Scholar 

  5. Bonadonna G, Valagussa P, Brambilla C et al. (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93–100

    PubMed  CAS  Google Scholar 

  6. Chevallier B, Roche H, Olivier J.P et al. (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. American Journal of Clinical Oncology 16: 223–8

    Article  PubMed  CAS  Google Scholar 

  7. Chevallier B., Chollet P., Merrouche Y. et al. (1995) Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13: 1564–71

    PubMed  CAS  Google Scholar 

  8. Chollet P, Charrier S, Brain E et al. (1997) Clinical and pathological response to primary chemotherapy in inoperable breast cancer. European Journal of Cancer 33: 862–6

    Article  PubMed  CAS  Google Scholar 

  9. Curé H, Charrier S, Ferrière JP et al. (1997) Chimiothérapie première dans les cancers du sein opérables supérieurs à 3 cm: résultats de 3 protocoles. Bulletin du Cancer 84: 31–4

    PubMed  Google Scholar 

  10. De Lena M, Varini M, Zucali R et al. (1981) Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 4: 229–36

    PubMed  Google Scholar 

  11. Diéras V, Fumoleau P, Romieu G et al. (1998) A randomized parallel study of doxorubicin/taxol (AT) and doxorubicine/cyclophosphamide (AC) as neoadjuvant treatment of breast cancer. Breast Cancer Res Treat 50: 233 (abst 25)

    Google Scholar 

  12. Fisher B, Brown A, Mamounas E et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings form National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–93

    PubMed  CAS  Google Scholar 

  13. Fumoleau P, Tubiana-Hulin M, Romieu G et al. (2001) A randomized phase II study of 4 or 6 cycles of adriamycin/taxol® (paclitaxel) as neoadjuvant treatment of breast cancer. Annals of Oncology, abst. 508.

    Google Scholar 

  14. Heys SD, Hutcheon AW, Sarkar TK et al. (2002) Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clinical Breast Cancer 3 Suppl 2: S69–74

    Article  Google Scholar 

  15. Hortobagyi GN, Ames FC, Buzdar AU et al. (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507–16

    Article  PubMed  CAS  Google Scholar 

  16. Jacquillat C, Weil M, Baillet F et al. (1990) Results of neoadjuvant chemotherapy and radiation therapy in the breast conservating treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119–29

    Article  PubMed  CAS  Google Scholar 

  17. Jaiyesimi IA, Buzdar AU, Hortobagyi G (1992) Inflammatory breast cancer: a review. J Clin Oncol 10: 1014–24

    PubMed  CAS  Google Scholar 

  18. Luporsi E, Vanlemmens L, Coudert B et al. (2000) 6 cycles of FEC 100 vs 6 cycles of Epirubicin Docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: preliminary results of a randomized phase II of GIREC S01. Proc Am Soc Clin Oncol 19: 92 a (abstr 355)

    Google Scholar 

  19. Mauriac L, Durand M, Avril A et al. (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 2: 347–54

    PubMed  CAS  Google Scholar 

  20. Mouret-Reynier MA, Abrial C, Ferrière JP et al. (2004) Neoadjuvant FEC 100 for operable breast cancer: Eight-year experience at Centre Jean-Perrin. Clinical Breast Cancer, (accepted)

    Google Scholar 

  21. Ogston KN, Miller ID, Payne S et al. (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast, 12: 320–7

    Article  PubMed  Google Scholar 

  22. Powles TJ, Hickish TF, Makris A et al. (1995) Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547–52

    PubMed  CAS  Google Scholar 

  23. Sataloff DM, Mason BA, Prestipino AJ et al. (1995) J Am Coll Surg, 180: 297–306

    PubMed  CAS  Google Scholar 

  24. Scholl SM, Fourquet A, Asselain B et al. (1994) Neoadjuvant versus adjuvant chemotherapy in premenaupausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645–52

    Article  PubMed  CAS  Google Scholar 

  25. Smith IE, Jones AL, O’Brien ME et al. (1993) Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29A: 592–5

    Google Scholar 

  26. Smith GA, Henderson IC (1995) High dose chemotherapy (HDC) with Autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out. Important advances in oncology 1995, edited by Vincent T De Vita, Samuel Hellman, and Steven A. Rosenberg. J.B. Lippincott company, Philadelphia

    Google Scholar 

  27. Smith IE, A’Hern R, Coombes G et al. (2003) A randomised neoadjuvant chemotherapy trial of Vinorelbine/Epirubicin (VE) vs standard Doxorubicin/Cyclophosphamide (DC) in patients with >=3 cm diameter operable breast cancer (topic 2). Proc Annu Meet Am Soc Clin Oncol, 22: 21-Abst.83

    Google Scholar 

  28. Van Praagh I, Curé H, Leduc B et al. (2002) Efficacy of primary chemotherapy regimen combining Vinorelbine, Epirubicine and Methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. The Oncologist, 7:418–23

    Article  PubMed  Google Scholar 

  29. Van Praagh I, Amat S, Leduc B et al. (2002) Induction chemotherapy in operable breast cancer by NET regimen: multicentric phase II trial. Annals of Oncology, 13: 43-abst.153

    Google Scholar 

  30. Viens P, Palangié T, Janvier M et al. (1999) Fist line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (Pegase 02 program). British Journal of Cancer 81: 449–56

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Jean Perrin, Bureau de recherche clinique, 58 rue Montalembert, BP 392, 63011, Clermont-Ferrand Cedex 1

    C. Abrial, F. Penault-Llorca, M. -A. Mouret-Reynier, H. Curé & P. Chollet

Authors
  1. C. Abrial
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Penault-Llorca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. -A. Mouret-Reynier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Curé
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Chollet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France

About this chapter

Cite this chapter

Abrial, C., Penault-Llorca, F., Mouret-Reynier, M.A., Curé, H., Chollet, P. (2007). Quand faire de la chimiothérapie néoadjuvante? Ľutilisation de la chimiothérapie néoadjuvante chez des patientes atteintes de cancer du sein opérable (stades II et III). In: Le cancer du sein. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-36073-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-36073-2_7

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-36071-8

  • Online ISBN: 978-2-287-36073-2

Publish with us

Policies and ethics

Search

Navigation